logo
logo
PEPG stock ticker logo

PepGen Inc.

NASDAQ•PEPG
CEO: Dr. James G. McArthur Ph.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2022-05-06
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.
Contact Information
321 Harrison Avenue, 8th Floor, Boston, MA, 02118, United States
781-797-0979
pepgen.com
Market Cap
$423.49M
P/E (TTM)
-4.7
17.5
Dividend Yield
--
52W High
$7.80
52W Low
$0.88
52W Range
76%
Rank58Top 85.6%
2.3
F-Score
Modified Piotroski Analysis
Based on 6-year fundamentals
Weak • 2.3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2020-2025

Financial Dashboard

Q4 2025 Data

Revenue

$0.00+0.00%
4-Quarter Trend

EPS

-$0.27+0.00%
4-Quarter Trend

FCF

-$15.84M+0.00%
4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

R&D Expenses Decreased R&D expenses totaled 71.0M USD in 2025, down 5.4M USD from 76.5M USD in 2024, reflecting strategic program prioritization.
Robust Cash Position Cash, cash equivalents, and marketable securities reached 148.5M USD as of December 31, 2025, supporting operations into second half of 2027.
Net Loss Narrowed Net loss for 2025 was 89.7M USD, compared to 90.0M USD in 2024, reflecting disciplined management of operating expenses and resources.

Risk Factors

Partial Clinical Hold FDA placed partial clinical hold on FREEDOM2 study due to questions regarding previously submitted preclinical pharmacology and toxicology studies, impacting development.
Lead Candidate Dependency Business success heavily dependent on PGN-EDODM1; failure to develop, obtain approval, or commercialize this lead candidate would materially harm financial condition.
Future Funding Requirements Significant additional capital required to advance PGN-EDODM1 beyond 2026; inability to raise funds could force program delays, reductions, or termination of operations.

Outlook

Upcoming Clinical Data Readouts Expect to report data from 5 mg/kg cohort in Q1 2026 and 10 mg/kg cohort in second half of 2026 for FREEDOM2.
EDO Platform Expansion Intend to utilize modular EDO platform to evaluate new cargos and peptide technologies, expanding scope of deliverable nucleic acid payloads long-term.
Commercial Infrastructure Planning Evaluating commercialization strategy for PGN-EDODM1, potentially utilizing targeted specialty sales and marketing organization to address limited patient population and prescribing audience.

Peer Comparison

Revenue (TTM)

CCCC stock ticker logoCCCC
$35.95M
+1.0%
ALEC stock ticker logoALEC
$21.05M
-79.1%
FATE stock ticker logoFATE
$6.65M
-51.2%

Gross Margin (Latest Quarter)

APLT stock ticker logoAPLT
100.0%
+0.0pp
CCCC stock ticker logoCCCC
83.6%
+13.4pp
ALEC stock ticker logoALEC
63.8%
+0.0pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
PEPG$423.49M-4.7-75.7%9.8%
CYBN$413.02M-1.7-61.5%15.9%
ALEC$262.66M-1.7-225.0%12.4%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Deep Research

Next earnings:May 6, 2026
|
EPS:-
|
Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data